Nothing Special   »   [go: up one dir, main page]

AU4459500A - A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine - Google Patents

A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine

Info

Publication number
AU4459500A
AU4459500A AU44595/00A AU4459500A AU4459500A AU 4459500 A AU4459500 A AU 4459500A AU 44595/00 A AU44595/00 A AU 44595/00A AU 4459500 A AU4459500 A AU 4459500A AU 4459500 A AU4459500 A AU 4459500A
Authority
AU
Australia
Prior art keywords
antagonist
reversing
administering
thymic atrophy
overproduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44595/00A
Inventor
Laura P Hale
Barton F. Haynes
Dhavalkumar D. Patel
Gregory D. Sempowski
John S. Sundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU4459500A publication Critical patent/AU4459500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU44595/00A 1999-04-15 2000-04-14 A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine Abandoned AU4459500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12936199P 1999-04-15 1999-04-15
US60129361 1999-04-15
PCT/US2000/010008 WO2000062805A1 (en) 1999-04-15 2000-04-14 A method of reversing thymic atrophy

Publications (1)

Publication Number Publication Date
AU4459500A true AU4459500A (en) 2000-11-02

Family

ID=22439598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44595/00A Abandoned AU4459500A (en) 1999-04-15 2000-04-14 A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine

Country Status (2)

Country Link
AU (1) AU4459500A (en)
WO (1) WO2000062805A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131619A1 (en) * 2002-09-30 2004-07-08 Duke University Thymic atrophy
CN105368841A (en) 2006-01-13 2016-03-02 美国政府健康及人类服务部国立卫生研究院 Improved il-15 and il-15r-alpha for expression in mammalian cells
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
AU6984594A (en) * 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof

Also Published As

Publication number Publication date
WO2000062805A8 (en) 2001-01-25
WO2000062805A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AUPP970099A0 (en) Concrete formulation
AU7315700A (en) Melanin concentrating hormone antagonist
AU2003268495A1 (en) Method for reservation-less instant group conferencing
AU5577096A (en) Sulfonylquinolines as neuropeptide y1 antagonists
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001271367A1 (en) Method and system for call administration
AU2001251083A1 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU2002338709A1 (en) Workability-improving agents for cement compositions
AU2003261627A1 (en) Resin mortar composition for construction and floor operating method using the same
AU2003215107A1 (en) Method of "wet-field" scanning
AU4150200A (en) Steel-frame structure and method of construction by using the same
AU2003300904A1 (en) Antagonists for human prolactin
AU768901C (en) Method for setting dental glass ionomer cement
AUPQ018999A0 (en) Compositions and methods for curing concrete
AU3086201A (en) Temporary dental cement compositions and related methods and systems
AU4459500A (en) A method of reversing thymic atrophy by administering an antagonist of an overproduced cytokine
AU6187898A (en) Method for preventing or treating low renin hypertension by administering an endothelin antagonist
AU2003275354A1 (en) Brick additives and methods for using same
AU2002251010A1 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
AU2003224808A1 (en) Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
AU2003275069A1 (en) Compositions and methods for preventing infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase